Artwork

Content provided by Clinical Care Options, LLC and Clinical Care Options. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Clinical Care Options, LLC and Clinical Care Options or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Congress to Clinic: Expert Takeaways on Emerging Data for MPNs

28:35
 
Share
 

Manage episode 428574032 series 3256997
Content provided by Clinical Care Options, LLC and Clinical Care Options. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Clinical Care Options, LLC and Clinical Care Options or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

In this episode, listen to Dr Brady L. Stein share his clinical insights and takeaways on new data for myeloproliferative neoplasms (MPNs) presented at the 2024 ASCO Annual Meeting and the EHA 2024 Congress including:

  • Long-term survival adjusted for treatment crossover in patients with myelofibrosis (MF) treated with momelotinib vs danazol in the MOMENTUM trial
  • Efficacy of pacritinib in patients with MF who have both thrombocytopenia and anemia
  • Updated safety and efficacy data from the phase III MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor–naive MF
  • Impact of spleen volume on post-allogenic hematopoietic transplant outcomes in patients with MF: utility of 3D volumetrics in splenomegaly
  • Progression to MF in patients with essential thrombocythemia: an analysis from the prospective MOST study
  • JAK2V617F molecular response correlates with event-free survival in a patient population with early polycythemia vera
  • Phase III TRANSFORM-1 study: efficacy and safety of navitoclax combined with ruxolitinib vs ruxolitinib plus placebo in patients with untreated MF
  • Patient characteristics, treatment patterns, and health outcomes in a real-world population of patients with MF treated with fedratinib

Program faculty:

Brady L. Stein, MD, MHS
Professor of Medicine
Department of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Resources:
To download the slides associated with this podcast discussion, please visit the program page.

  continue reading

175 episodes

Artwork
iconShare
 
Manage episode 428574032 series 3256997
Content provided by Clinical Care Options, LLC and Clinical Care Options. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Clinical Care Options, LLC and Clinical Care Options or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

In this episode, listen to Dr Brady L. Stein share his clinical insights and takeaways on new data for myeloproliferative neoplasms (MPNs) presented at the 2024 ASCO Annual Meeting and the EHA 2024 Congress including:

  • Long-term survival adjusted for treatment crossover in patients with myelofibrosis (MF) treated with momelotinib vs danazol in the MOMENTUM trial
  • Efficacy of pacritinib in patients with MF who have both thrombocytopenia and anemia
  • Updated safety and efficacy data from the phase III MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor–naive MF
  • Impact of spleen volume on post-allogenic hematopoietic transplant outcomes in patients with MF: utility of 3D volumetrics in splenomegaly
  • Progression to MF in patients with essential thrombocythemia: an analysis from the prospective MOST study
  • JAK2V617F molecular response correlates with event-free survival in a patient population with early polycythemia vera
  • Phase III TRANSFORM-1 study: efficacy and safety of navitoclax combined with ruxolitinib vs ruxolitinib plus placebo in patients with untreated MF
  • Patient characteristics, treatment patterns, and health outcomes in a real-world population of patients with MF treated with fedratinib

Program faculty:

Brady L. Stein, MD, MHS
Professor of Medicine
Department of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Resources:
To download the slides associated with this podcast discussion, please visit the program page.

  continue reading

175 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide